TITLE

Current Challenges in the Treatment of Community-Acquired Pneumonia

AUTHOR(S)
File Jr., Thomas M.
PUB. DATE
January 2004
SOURCE
Clinical Infectious Diseases;1/15/2004 Supplement 1, Vol. 38, pS1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The respiratory fluoroquinolones are considered to be an effective treatment option for community-acquired pneumonia (CAP), and they are the recommended first-line treatment for certain patients. However, the development of resistance associated with the widespread use of these agents has raised concern about the future clinical value of this class of antibiotics. The 4 articles in this supplement issue of Clinical Infectious Diseases reveal clinical data on the safety and efficacy of a fluoroquinolone, levofloxacin, used for the treatment of CAP and CAP-associated infections, including those caused by penicillin- and macrolide-resistant Streptococcus pneumoniae. Future strategies of fluoroquinolone use may improve clinical efficacy and reduce the risk of the emergence of resistance. However, judicious use of antibiotics should always be a high priority when considering treatment of respiratory tract infections.
ACCESSION #
12082018

 

Related Articles

Share

Read the Article

Courtesy of

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics